Free Trial 中
Wind ESG Rating

Access to ESG rating for China A-Shares and Hong Kong listed companies.

三元基因

920344.BJ
Wind Industry: 医疗保健 > 医药生物 > 生物科技Ⅲ > 生物科技Ⅳ

公司主要从事现代生物医药产品的研究、开发、生产和销售，是中国基因工程药物基础研究和临床应用开发领域的领先企业。公司产品主要包括多种剂型和规格的重组人干扰素α1b，以该产品为首的“基因工程人α型干扰素系列产品的研制生产和应用”项目曾荣获国家科学技术进步奖一等奖。其中，注射用重组人干扰素α1b、重组人干扰素α1b注射液已列入《国家基本医疗保险、工伤保险和生育保险药品目录》和《国家基本药物目录(2018年版)》。

ESG Score Industry Ranking:
7 / 165 (生物科技Ⅲ)

ESG Rating Distribution(生物科技Ⅲ)

Trend of Rating

2022-08-01: BB; 2023-08-01: BBB; 2024-08-31: A; 2025-07-05: A; 2026-07-25: AA BB2022.08 BBB2023.08 A2024.08 A2025.07 AA2026.07

About Wind ESG Rating

Wind has developed a rigorous rating methodology based on the core connotations of ESG, aligning with international standards and frameworks, and incorporating the characteristics of Chinese companies, to assess the company's essential ESG performance, risk and its ability to operate sustainably.

Focusing on the ESG risks and opportunities of each industry, the companies are rated on a AAA-CCC scale relative to the performance of their industry peers. Wind ESG rating is updated annually or in response to major changes.

The Wind ESG Rating Issuer Communication Platform (esg.wind.com.cn) is now available. Rated companies can access their detailed rating information through this platform, and communicate with or provide feedback to the Wind ESG Rating team regarding specific rating components. For any additional questions, please feel free to send an email to GR.ESG@wind.com.cn.

ESG Score

ESG Score：8.16Updated on 2026-10-29
08.1610
Management & Practices Score：5.20Updated on 2026-09-16
05.207
Controversies Score：2.96Updated on 2026-10-29
02.963

ESG Score Comparison

Environmental Social Governance 三元基因生物科技Ⅲ Average
IndicatorCompany ScoreIndustry AverageWeight
Environmental4.333.6712.53%
Social7.974.5457.57%
Governance7.695.7829.91%

Wind ESG Rating Framework

Building on the foundation of domestic and international ESG policies and standards, our proprietary ESG rating framework considers the development of Chinese capital market and integrates the characteristics of the Chinese companies in various industries. The Wind ESG Rating framework is composed of management & practice and controversies assessment, including:

  • 500+ management & practices indicators, covering E, S and G pillars, reflecting long-term ESG fundamental impacts
  • 1,200+ risk labels, covering news, regulatory penalties and lawsuits, reflecting impact of short-term risks

Management & practice score is the weighted summation of E, S and G pillar scores. The weights reflect both the relative impact of each issue within each industry and the negative or positive contribution of each industry to the environment and society relative to other industries.

Controversies score and ESG score are updated daily, E, S and G pillar scores and management & practice score are updated with underlying data, corresponding data are released on various channels, including Wind Financial Terminal.

Explore More

Wind ESG Rating Methodology.pdf1,198KB Wind ESG Ratings FAQs.pdf755KB
More Details

Peer Comparison(165 companies in the industry) ?

RankingCodeSecurity NameESG RatingESG ScoreControversies ScoreManagement & Practices ScoreEnvironmentalSocialGovernance
1603392.SH万泰生物AA8.862.965.907.578.548.58
2002252.SZ上海莱士AA8.682.995.697.758.128.29
31801.HK信达生物AA8.623.005.627.788.038.12
4300142.SZ沃森生物AA8.422.945.485.488.148.21
52269.HK药明生物AA8.283.005.288.457.477.29
61530.HK三生制药AA8.262.995.267.567.437.68
7920344.BJ三元基因AA8.162.965.204.337.977.69
7300122.SZ智飞生物AA8.162.975.195.407.428.24
96660.HK艾美疫苗AA8.123.005.126.397.377.57
106855.HK亚盛医药AA8.112.995.127.217.736.59